Evidence map›Paper›PMID 32727497›Full record

Trial reportRadiation oncology (London, England)2020

Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.

Jin Huang, Fei Gu, Tianlong Ji, Jing Zhao, Guang Li

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Radiation oncology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Optimising chemoradiotherapy in anal cancer.ESMO gastrointestinal oncology · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jin HuangDepartment of radiotherapy, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.
Fei GuDepartment of radiotherapy, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.
Tianlong JiDepartment of radiotherapy, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.
Jing ZhaoDepartment of radiotherapy, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.
Guang LiDepartment of radiotherapy, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, Liaoning, China. dr_liguang@163.com.

Funding

Chinese Society of Clinical Oncology Y-G201801-055
6 · The paper itself

Abstract

purposeTo test the efficacy and feasibility of pelvic bone marrow sparing intensity modulated radiotherapy (PBMS-IMRT) in reducing grade 2 or higher hematological toxicity (HT2+) for patients with cervical cancer treated with concurrent chemoradiotherapy. METHODS AND MATERIALS: A total of 164 patients with Stage Ib2-IIIb cervical cancer were prospectively enrolled from March 2018 to March 2019 at a single center and were randomly allocated into the PBMS group or the control group. The control group received weekly cisplatin concurrently with IMRT, followed by intracavitary brachytherapy. The PBMS group additionally received PBM dose constraint. The dosimetric parameters of the pelvic bone (PB) and the subsites including hip bone (HIP) and lumbosacral spine (LSS) and the corresponding bone marrow were recorded. The endpoint of the trial was acute hematologic or gastrointestinal toxicity. Receiver operating characteristic curves were used to derive optimal dosimetric planning constraints.

resultsEighty-two patients in the PBMS group and 82 in the control group were enrolled for statistical analysis. The incidence of HT2+ in the PBMS group was 50.0%, significantly lower than the 69.5% incidence in the control group (P = 0.02). Patients with PB V40 ≥ 28% were more likely to experience HT2+ (OR = 2.85, P = 0.006), while the incidence of grade 2 or higher gastrointestinal toxicity (GT2+) events did not differ significantly between the two groups (P > 0.05). Dosimetric parameters of LSS showed stronger associations with HT2+ than other subsites. The patients with LSS V10 ≥ 87% and LSS mean ≥ 39 Gy were more likely to experience HT2+ (OR = 3.13, P = 0.001;OR = 3.03, P = 0.002, respectively).

conclusionPBMS-IMRT reduced HT compared with IMRT alone. Efforts to maintain LSS V10 < 87%, LSS mean < 39 Gy and PB V40 < 28% simultaneously may reduce the risk of HT2 +.

trial registrationThe trial was registered with Chinese clinical trial registry ( ChiCTR1800015069 ).

Indexed as

ChemoradiotherapyAdultAgedBone MarrowCisplatinFemaleHumansIncidenceLogistic ModelsMiddle AgedPelvic BonesProspective StudiesRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedUterine Cervical NeoplasmsCisplatinCervical cancerHematological toxicityPelvic bone marrow sparing intensity modulated radiotherapy (PBMS-IMRT)

Identifiers

PMID32727497
PMCPMC7389381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.